Meta- analysis of BMI values at end of trial showed no statistically significant difference in BMI change by use of 25[OH]D supplementation .
Based on existing published trials , oral 25[OH]D supplementation does not significantly impact BMI change
The impact of 25-hydroxyvitamin D ( 25[OH]D ) supplementation on weight change remains controversial .
The objective of this study was to summarize the effects of 25[OH]D supplementation ( cholecalciferol or ergocalciferol ) on BMI change through a meta- analysis of published clinical trials .
Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects.
OBJECTIVE Investigate whether cholecalciferol supplementation leads to weight loss in overweight and obese adults . DESIGN R and omized double blind clinical trial with 20,000 IU cholecalciferol twice a week , or 20,000 IU once a week plus placebo , or placebo twice a week , for 12 months . All subjects were given 500 mg calcium supplementation . METHODS Four hundred and forty five healthy , overweight , and obese men and women ( age 21 - 70 years , body mass index ( BMI ) 28.0 - 47.0 kg/m(2 ) ) .  Body weight , fatness , and fat distribution parameters were measured by dual-energy X-ray absorptiometry and anthropometry , blood sample s and 24-h urinary sample s were collected . RESULTS At baseline , there were no significant differences between the groups , but there was a significant inverse relation between serum 25-hydroxyvitamin D ( 25(OH)D ) levels and BMI , and a significant positive association between calorie intake and BMI .  Three hundred and thirty four subjects completed the study . During the study , there was no significant change in weight , waist-to-hip ratio ( WHR ) or percentage body fat in any of the groups , nor between them . Parathyroid hormone decreased and 25(OH)D increased significantly in both groups receiving cholecalciferol , and serum levels of 25(OH)D stabilized after 3 months . Serum calcium was unchanged in all groups . Urinary calcium excretion increased in all groups , but there was no significant difference between the groups . Weekly dosage of 20,000 - 40,000 IU cholecalciferol for 12 months was associated with a low risk of adverse effects , at least in overweight and obese adults living at latitude 70 degrees N. CONCLUSION Significant weight reduction in overweight and obese subjects is unlikely to occur with cholecalciferol supplementation
Meta- analysis of BMI values at end of trial showed no statistically significant difference in BMI change by use of 25[OH]D supplementation .
Based on existing published trials , oral 25[OH]D supplementation does not significantly impact BMI change
The impact of 25-hydroxyvitamin D ( 25[OH]D ) supplementation on weight change remains controversial .
The objective of this study was to summarize the effects of 25[OH]D supplementation ( cholecalciferol or ergocalciferol ) on BMI change through a meta- analysis of published clinical trials .